Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
155
Recruiting, industry sponsors, Hematology and blood cancers, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting155
- Completed859
155 trials
Showing 1 to 25, recently updated first.
- Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
CellCentric Ltd.Industry
NCT07772024 · 450 participants (planned) · Start Nov 18, 2026 · Primary completion Nov 2029
Drug: InoPd; Investigator's choice of SAT · For: Multiple Myeloma Refractory; Multiple Myeloma in Relapse
Sites: Solvang, California; Miami, Florida; Saint Augustine, Florida · 11 sites in all
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPivotal-lookingRecruiting
Pierre Fabre MedicamentIndustry
NCT03394365 · 115 participants (planned) · Start Dec 29, 2017 · Primary completion May 31, 2030
Drug: tabelecleucel · For: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders and 2 more
Sites: Duarte, California; La Jolla, California; Loma Linda, California · 72 sites in all
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Pivotal-lookingRecruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07104032 · 132 participants (planned) · Start Jun 12, 2026 · Primary completion Dec 2027
Drug: Tirabrutinib; Rituximab and 1 more · For: Relapsed/Refractory Primary Central Nervous System Lymphoma
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fullerton, California · 50 sites in all
- A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency AnemiaPivotal-lookingRecruiting
AFT Pharmaceuticals, Ltd.Industry
NCT07687784 · 1,366 participants (planned) · Start Nov 2026 · Primary completion Jun 2028
Drug: Ferric Bepectate IV Injection; Ferric Carboxymaltose Injection [Ferinject] and 1 more · For: Iron Deficiency Anemia (IDA)
Sites: Phoenix, Arizona; Coral Gables, Florida; Lake City, Florida · 24 sites in all
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Pivotal-lookingRecruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06615479 · 440 participants (planned) · Start Mar 12, 2025 · Primary completion Dec 30, 2027
Drug: BMS-986393; Cyclophosphamide and 5 more · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 141 sites in all
AbbVieAbbVie (ABBV)
NCT07581002 · 660 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2032
Drug: Pivekimab Sunirine; Venetoclax and 2 more · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 40 sites in all
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07555938 · 380 participants (planned) · Start Jun 23, 2026 · Primary completion Nov 30, 2028
Drug: Cevostamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; New Haven, Connecticut · 105 sites in all
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05611801 · 100 participants (planned) · Start Dec 9, 2022 · Primary completion Sep 10, 2028
Drug: marstacimab · For: Hemophilia A; Hemophilia B
Sites: Salt Lake City, Utah; Mendoza, Argentina; Parkville, Australia · 62 sites in all
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaPivotal-lookingRecruiting
Quetzal TherapeuticsIndustry
NCT07504458 · 150 participants (planned) · Start Jun 8, 2026 · Primary completion Mar 2027
Drug: QTX-2101 + ATRA; IV arsenic trioxide (ATO) + ATRA · For: Acute Promyelocytic Leukemia (APL); Acute Promyelocytic Leukaemia; Acute Promyelocytic Leukemia With PML-RARA and 2 more
Sites: Birmingham, Alabama; Duarte, California; Irvine, California · 39 sites in all
- The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06975865 · 192 participants (planned) · Start Aug 12, 2025 · Primary completion Jul 23, 2027
Drug: Rilzabrutinib; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Clovis, California · 64 sites in all
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Pivotal-lookingRecruiting
Kind Pharmaceuticals LLCIndustry
NCT07487727 · 240 participants (planned) · Start Dec 3, 2025 · Primary completion Mar 1, 2027
Drug: AND017; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Beijing, China
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaPivotal-lookingRecruiting
Hemab ApSIndustry
NCT07935356 · 76 participants (planned) · Start Oct 27, 2026 · Primary completion Nov 2029
Drug: Sutacimig · For: Thrombasthenia
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 9 sites in all
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsPivotal-lookingRecruiting
Enliven TherapeuticsIndustry
NCT07905183 · 450 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2028
Drug: ELVN-001; TKI · For: Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Sites: Atlanta, Georgia; Indianapolis, Indiana; Morristown, New Jersey · 4 sites in all
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07700238 · 126 participants (planned) · Start Oct 15, 2026 · Primary completion Sep 14, 2029
Drug: Romiplostim; Predniso(lo)ne · For: Primary Immune Thrombocytopenia
Sites: Long Beach, California; Peoria, Illinois; Durham, North Carolina · 21 sites in all
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07222761 · 915 participants (planned) · Start Jan 2, 2026 · Primary completion May 21, 2029
Drug: Linvoseltamab; Carfilzomib and 4 more · For: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sites: Atlanta, Georgia; Ann Arbor, Michigan; New York, New York · 60 sites in all
- A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07086976 · 90 participants (planned) · Start Aug 18, 2025 · Primary completion May 31, 2028
Drug: rilzabrutinib; placebo · For: Autoimmune Haemolytic Anaemia
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 105 sites in all
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06980480 · 183 participants (planned) · Start Jan 14, 2026 · Primary completion Sep 11, 2028
Drug: IGI, 10% · For: Multiple Myeloma; Secondary Immunodeficiency
Sites: Mobile, Alabama; Orange, California; Westwood, Kansas · 68 sites in all
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05947851 · 735 participants (planned) · Start Aug 8, 2023 · Primary completion Jun 1, 2032
Drug: Nemtabrutinib; Venetoclax and 1 more · For: Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma and 3 more
Sites: Springdale, Arkansas; Long Beach, California; Clermont, Florida · 107 sites in all
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07728188 · 520 participants (planned) · Start Oct 20, 2026 · Primary completion Feb 2033
Drug: Etentamig; Pomalidomide and 4 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Ogden, Utah; Jerusalem, Israel; Kyoto, Japan · 7 sites in all
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136559 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 7, 2032
Drug: Nemtabrutinib; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 206 sites in all
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Pivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT05303519 · 365 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 1, 2028
Drug: safusidenib; Placebo · For: Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 75 sites in all
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLPivotal-lookingRecruiting
Newave Pharmaceutical IncIndustry
NCT07342478 · 306 participants (planned) · Start Apr 23, 2026 · Primary completion Oct 30, 2029
Drug: Rocbrutinib; Pirtobrutinib · For: CLL / SLL; CLL (Chronic Lymphocytic Leukemia); CLL, Refractory and 5 more
Sites: Skokie, Illinois; Bethesda, Maryland; Las Vegas, Nevada · 10 sites in all
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07194850 · 24 participants (planned) · Start Oct 20, 2025 · Primary completion Oct 2028
Drug: Efgartigimod IV · For: Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP and 4 more
Sites: Bordeaux, France; La Tronche, France; Vandœuvre-lès-Nancy, France · 28 sites in all
- A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaPivotal-lookingRecruiting
Aldeyra Therapeutics, Inc.Industry
NCT07402876 · 20 participants (planned) · Start Dec 2027 · Primary completion Dec 2029
Drug: ICM ADX-2191 injection; Monthly ADX-2191 injection · For: Primary Vitreoretinal Lymphoma
Sites: Miami, Florida
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07925190 · 318 participants (planned) · Start Nov 3, 2026 · Primary completion Dec 2029
Drug: Mesutoclax (ICP-248); Azacitidine (AZA) and 1 more · For: Acute Myeloblastic Leukemia
Sites: Hangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.